Watson Pharmaceuticals announced that it has received final FDA approval for its generic drug, Accuneb.
Accuneb is an alubterol sulfate inhalation solution, the generic equivalent of Dey, L.P.’s AccuNeb Inhalation Solution, is used for relief of bronchospam in patients between the ages of 2 and 12 with asthma.
Watson has secured a six month market exclusivity from the date of commercial launch which Watson plans to do immediately.
Watson Pharmaceuticals Inc. is headquartered in Corona, CA. It is a leading specialty pharmaceutical company that develops, manufactures markets and sells brand and generic drugs.
Comment Preview